Donor-derived membranous nephropathy in the allograft kidney: A rare but probably underestimated complication

Rachel A Nuccitelli1, Hilda E Fernandez2, S Ali Husain2

  • 1Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA.

Insights

Donor-derived membranous nephropathy (MN) is a rare kidney transplant complication, even in living donors. This condition, often phospholipase A2 receptor-negative, can occur despite thorough donor screening and typically results in mild proteinuria without significant kidney function decline.

Area of Science:

  • Nephrology
  • Transplant Immunology
  • Pathology

Background:

  • Transmitted donor-derived glomerular diseases are rare in kidney allografts, particularly from living donors.
  • Previous reports of donor-derived membranous nephropathy (MN) are limited to individual cases.

Observation:

  • A case of MN was identified in a postreperfusion biopsy of a living-donor kidney allograft.
  • Follow-up biopsies confirmed persistent immune deposits.
  • Analysis included 7 in-house cases and 6 literature cases, with a minority of donors being living.

Findings:

  • Most donors with transmitted MN did not exhibit significant proteinuria, suggesting predonation screening may miss this condition.
  • Immune deposits were phospholipase A2 receptor-negative and thrombospondin type 1 domain containing 7A-negative in all evaluated cases.
  • Recipients showed variable resolution of immune deposits, mainly subnephrotic proteinuria, and stable kidney function post-transplant.

Implications:

  • Donor-derived MN is an exceedingly rare complication that can occur even in living kidney donors despite rigorous screening.
  • The condition is typically phospholipase A2 receptor-negative and does not lead to significant long-term kidney function impairment.
  • Understanding the pathology, clinical course, and laboratory features is crucial for managing this rare entity.